{"id":"morphine-sulfate-sustained-release-tablet","safety":{"commonSideEffects":[{"rate":"10-30%","effect":"Nausea"},{"rate":"5-20%","effect":"Vomiting"},{"rate":"10-30%","effect":"Constipation"},{"rate":"5-20%","effect":"Dizziness"},{"rate":"5-20%","effect":"Somnolence"}]},"_chembl":{"chemblId":"CHEMBL2103744","moleculeType":"Small molecule","molecularWeight":"758.84"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Morphine sulfate is a mu-opioid receptor agonist that activates the G-protein coupled receptor, leading to the inhibition of adenylate cyclase and a decrease in the release of neurotransmitters involved in pain perception. This results in analgesia and a reduction in emotional responses to pain.","oneSentence":"Morphine sulfate works by binding to opioid receptors in the brain and spinal cord, producing analgesia and altering emotional responses to pain.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:22:04.705Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate to severe pain"},{"name":"Severe pain in cancer patients"}]},"trialDetails":[{"nctId":"NCT05265052","phase":"PHASE2","title":"3D1002 in Combination With Oxycodone Hydrochloride Sustained-release Tablets in Patients With Moderate to Severe Cancer Pain","status":"NOT_YET_RECRUITING","sponsor":"3D Medicines","startDate":"2026-12","conditions":"Cancer Pain","enrollment":177},{"nctId":"NCT04785768","phase":"PHASE3","title":"IV PCA With or Without Continuous Dose vs Oral Opioid to Maintain Analgesia for Severe Cancer Pain After Successful Titration","status":"COMPLETED","sponsor":"Fujian Cancer Hospital","startDate":"2021-07-01","conditions":"Cancer Pain","enrollment":1372},{"nctId":"NCT06897917","phase":"PHASE4","title":"Real World Study of Oxycodone/Naloxone Sustained-Release Tablets (Mimeixin) for Patients With Severe Cancer Pain","status":"NOT_YET_RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2025-04","conditions":"Opioid-Induced Constipation, Pain Cancer","enrollment":203},{"nctId":"NCT04549818","phase":"NA","title":"Analgesic Efficacy of Sacral Neuromodulation for Pelvic Cancer Pain: A Preliminary Report","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2020-09-10","conditions":"Chronic Pain","enrollment":44},{"nctId":"NCT04132011","phase":"PHASE4","title":"Dosing Intervals of Opioid Medication for Chronic Pain","status":"WITHDRAWN","sponsor":"University Health Network, Toronto","startDate":"2019-05-01","conditions":"Chronic Pain","enrollment":""},{"nctId":"NCT02429050","phase":"PHASE4","title":"Morphine for Treatment of Dyspnea in Patients With COPD","status":"COMPLETED","sponsor":"Maastricht University Medical Center","startDate":"2016-11-16","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":124},{"nctId":"NCT03967327","phase":"PHASE3","title":"A Study to Evaluate Buprenorphine Transdermal Patch in Chinese Subjects With Moderate to Severe Chronic Cancer Pain","status":"UNKNOWN","sponsor":"Mundipharma (China) Pharmaceutical Co. Ltd","startDate":"2019-04-22","conditions":"Cancer Pain","enrollment":194},{"nctId":"NCT02198924","phase":"PHASE4","title":"Efficacy and Safety of Postoperative Intravenous Parecoxib Sodium Followed by Oral Celecoxib in Osteoarthritis Patients","status":"COMPLETED","sponsor":"Peking Union Medical College Hospital","startDate":"2014-12","conditions":"Pain, Inflammation","enrollment":246},{"nctId":"NCT01549652","phase":"NA","title":"5HT3 Antagonists to Treat Opioid Withdrawal and to Prevent the Progression of Physical Dependence","status":"COMPLETED","sponsor":"Stanford University","startDate":"2011-04","conditions":"Opioid Withdrawal, Physical Dependence","enrollment":133},{"nctId":"NCT00314340","phase":"PHASE4","title":"A Comparison of the Addiction Liability of Hydrocodone and Sustained Release Morphine","status":"COMPLETED","sponsor":"University of California, Davis","startDate":"2005-11","conditions":"Chronic Pain","enrollment":12},{"nctId":"NCT00943566","phase":"PHASE2","title":"A Safety and Efficacy Study of Sufentanil Transdermal System in Patients With Chronic Pain Due to Cancer","status":"WITHDRAWN","sponsor":"Labtec GmbH","startDate":"2010-01","conditions":"Chronic Pain","enrollment":""},{"nctId":"NCT00805142","phase":"PHASE2","title":"Phase 2 Study of Tapentadol Prolonged Release in Cancer Pain Participants","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2008-11","conditions":"Pain, Cancer","enrollment":78},{"nctId":"NCT01309386","phase":"PHASE3","title":"A Safety and Efficacy Study of Oral Tapentadol Extended-Release in Japanese Participants","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2010-08","conditions":"Neoplasms","enrollment":100}],"_emaApprovals":[],"_faersSignals":[{"count":3,"reaction":"ANAEMIA"},{"count":2,"reaction":"HYPOKALAEMIA"},{"count":1,"reaction":"ACUTE KIDNEY INJURY"},{"count":1,"reaction":"AGRANULOCYTOSIS"},{"count":1,"reaction":"ALANINE AMINOTRANSFERASE INCREASED"},{"count":1,"reaction":"BACTERIAL SEPSIS"},{"count":1,"reaction":"BLOOD ALKALINE PHOSPHATASE INCREASED"},{"count":1,"reaction":"BLOOD BILIRUBIN INCREASED"},{"count":1,"reaction":"BLOOD CREATININE INCREASED"},{"count":1,"reaction":"DIARRHOEA"}],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Morphine Sulfate Sustained-Release Tablet","genericName":"Morphine Sulfate Sustained-Release Tablet","companyName":"Mundipharma (China) Pharmaceutical Co. Ltd","companyId":"mundipharma-china-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Morphine sulfate works by binding to opioid receptors in the brain and spinal cord, producing analgesia and altering emotional responses to pain. Used for Moderate to severe pain, Severe pain in cancer patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}